Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Blood Based Biomarkers Market Growth Potential: How Will Market Size Shift Through 2030?
The blood based biomarkers market size has experienced significant expansion in recent years. This market is projected to increase from $25.83 billion in 2025 to $28.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.0%. The historical growth of this market is largely attributable to advancements in molecular diagnostics, the development of cancer screening programs, comprehensive biomarker validation studies, enhancements in hospital diagnostic infrastructure, and a rise in research funding.
The blood based biomarkers market is projected to experience substantial expansion in the coming years, reaching $45.5 billion in 2030 with a compound annual growth rate (CAGR) of 12.0%. This anticipated growth during the forecast period is driven by factors such as the increasing use of liquid biopsy, advancements in AI-powered biomarker analytics, the rising need for chronic disease monitoring, the uptake of personalized medicine, and the proliferation of point-of-care testing. Key developments anticipated over the forecast period encompass a wider embrace of non-invasive diagnostics, the broadening of precision oncology applications, an elevated role in early disease detection, a heightened requirement for personalized treatment monitoring, and greater integration with clinical decision support systems.
Get A Free Sample Report With In-Depth Market Insights:
Blood Based Biomarkers Market Growth Drivers: What’s Behind The Acceleration?
An anticipated increase in cardiovascular disease incidents is set to boost the expansion of the blood-based biomarkers market. Cardiovascular diseases encompass various ailments impacting the heart and blood vessels, such as coronary artery disease, heart failure, and stroke. This surge in cardiovascular diseases can primarily be attributed to escalating risk factors like unhealthy diets and growing obesity levels. Blood-based biomarkers assist in the diagnosis and monitoring of these conditions by offering insights into how the disease advances, assessing risks, and evaluating treatment effectiveness, all through measurable substances found in the blood. For example, the National Center for Biotechnology Information, a US government agency, issued a global health research report in September 2024. Its forecasts projected a 90% increase in cardiovascular disease prevalence from 2025 to 2050, with cardiovascular deaths estimated to reach 35.6 million by 2050. Consequently, the expanding occurrence of cardiovascular diseases is a key factor propelling the growth of blood-based biomarkers.
Blood Based Biomarkers Market Segment Breakdown: Which Categories Lead On Revenue?
The blood based biomarkers market covered in this report is segmented –
1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers
2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies
3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications
4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users
Subsegments:
1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions
2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins
3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels
4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells
5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity
Blood Based Biomarkers Market Trends: What’s Defining The Industry’s Next Phase?
Companies operating in the blood-based biomarkers market are emphasizing technological advancements, such as high-accuracy blood biomarker tests, to aid physicians in diagnosing Alzheimer’s disease. A high-accuracy blood biomarker test functions as a diagnostic instrument that utilizes particular biomarkers in the blood to detect conditions or monitor health with a significant level of precision and reliability. For example, in October 2023, Quanterix, a US-based life sciences company, launched the LucentAD p-Tau 217, a high-accuracy blood biomarker test designed to assist physicians in diagnosing Alzheimer’s disease (AD) in adults exhibiting cognitive impairment. This test measures phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker closely linked to AD pathology, particularly amyloid buildup in the brain. The LucentAD p-Tau 217 test achieves over 90% accuracy, meeting strict diagnostic criteria, and is meant to be used alongside other diagnostic tools rather than as a standalone examination.
Blood Based Biomarkers Market Leading Players And Competitive Positioning
Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG
View The Full Blood Based Biomarkers Market Report:
Blood Based Biomarkers Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the blood-based biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model